The news of Purdue Pharma’s intention to rival Zohydro has caused the drug’s maker, Zogenix, to see its stock drop by more than 20 percent.
The makers of OxyContin have delivered a potentially devastating blow to the controversial new drug Zohydro – which produces an effect five to 10 times stronger than Vicodin – by revealing that they plan to submit an “abuse-resistant” painkiller to the Food and Drug Administration.
Purdue Pharma, which created MS Contin in 1984 and OxyContin in 1996, completed testing on a version of hydrocodone that cannot be crushed so abusers can snort or inject the drug. The new painkiller will be submitted to the FDA later this year, but it has already had a negative impact on Zohydro and its maker, Zogenix, which experienced a drop in shares by more than 20 percent following Purdue’s announcement.
The news is the latest in a series of public condemnations from the medical community directed toward Zohydro, a pure form of hydrocodone which was approved by the FDA in 2013 despite a lack of an abuse-deterrent formulation – an additive like naloxone or niacin which would cause an adverse effect if ingested by injection or snorting, but would remain inactive if consumed orally and absorbed into the gastrointestinal tract. The agency even ignored an 11-2 vote against approving the drug by their own scientific advisory panel.
The decision spurred a letter of protest from more than 40 doctors, addiction specialists, and lawmakers urging the FDA to reconsider its decision, given the recent overwhelming rate of painkiller addiction across the United States and elsewhere, as well as the inherent dangers of the drug. In the letter, the authors said that Zohydro is powerful enough to cause a fatal overdose in a person unaccustomed to taking opioids with just two capsules.
One of the letter’s signatories, Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing, summed up the drug’s potential by stating, “It will kill people as soon as it’s released.” In response, Zogenix has posted a warning about the drug’s potential side effects on its site and established an external safe-use board to oversee “appropriate use” of Zohydro.